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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: Bronchopulmonary dysplasia (BPD) of prematurity is associated with impaired
angiogenesis. Excess soluble fms-like tyrosine kinase-1 (sFlt-1) and lower levels of vascular
endothelial growth factor (VEGF) impaired alveolarization in preterm rats. Overexpression
of placenta growth factor (PlGF) in mice caused airspace enlargement, which is similar to
BPD pathologically. Our study aimed to clarify whether cord blood levels of these angiogenic
factors were associated with the development of BPD in preterm infants.
Methods: Preterm infants of gestational age (GA) <35 weeks who already had all the data of
cord blood VEGF, PlGF, and sFlt-1 levels in our previous studies were enrolled. Cord blood
levels of VEGF, PlGF, and sFlt-1 were collected. BPD was defined as the need for supplemental
oxygen or mechanical ventilation support at the postmenstrual age of 36 weeks. We used the
Mann-Whitney U test for comparison between infants with and without BPD, and multivariate
analysis with logistic regression to assess the association of these molecules and the develop-
ment of BPD.
Results: Infants with BPD had lower GA [(27 weeks (24e34) vs. 31 weeks (28e24)], lower birth
body weight [882 g (620e1232) vs. 1538 g (886e2328)], a higher incidence of respiratory
distress syndrome (RDS) (58% vs. 14%), and a higher level of PlGF [21.45 pg/dL (6.03
e474.01) vs. 7.43 pg/dL (0.09e23.75)] as compared with those infants without BPD. The levels
of VEGF and sFlt-1 did not differ significantly between the two groups. Multivariate logistic
regression revealed that lower birth body weight (p Z 0.022) and higher level of PlGF
(p Z 0.012) were significantly correlated with the development of BPD independently. There
was no significant association between the level of VEGF or sFlt-1 and the development of BPD.of Pediatrics, National Taiwan University Hospital, Number 7, Chung-Shan South Road, Taipei 100,
w (P.-N. Tsao).
015.02.001
Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Angiogenic Factors in Cord Blood 383Conclusion: Cord blood level of PlGF, rather than VEGF or sFlt-1, was significantly increased in
the BPD group. Consistent with our previous report, cord blood level of PlGF may be considered
as a biomarker to predict subsequently developing BPD in preterm infants.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Bronchopulmonary dysplasia (BPD), a chronic lung disease
followed by oxygen therapy and mechanical ventilator
support, is one of the most common complications in pre-
term infants.1 Indeed, it accounts for significant morbid-
ities and mortalities for those who are born prematurely.
With the introduction of antenatal steroid, exogenous sur-
factant, and greatly improved perinatal care, preterm in-
fants who develop BPD are now more immature than
formerly, and their clinical courses and pathological find-
ings are also different.2,3 Jobe4 brought up the concept of
“New BPD”, which indicated that arrest of lung develop-
ment instead of severe lung damage may presently be the
major mechanism of BPD.
The causes of lung development arrest have been widely
investigated. In recent years, ever more evidence and
studies have suggested that appropriate angiogenic status
is required for adequate pulmonary vascular development
that could support normal alveolar lung growth.5e7
Recently, Abman8 proposed a vascular hypothesis that
disruption of angiogenesis during lung development could
impair normal lung growth including decreased alveolari-
zation and decreased pulmonary arterial density, which
were the typical characteristics of new BPD.
Vascular endothelial growth factor (VEGF) signaling is
important for lung development. Inhibition of VEGF signaling
led to abnormal pulmonary vascular growth and impaired
alveolarization in several animal studies.5,6,9e11 By contrast,
excessive amniotic soluble fms-like tyrosine kinase-1 (sFlt-
1), an endogenous VEGF antagonist contributing to the
pathogenesis of preeclampsia, was documented to reduce
alveolar number and arterial density in preterm rats.9 In
addition, placental growth factor (PlGF), a member of the
VEGF family, mediates angiogenesis by modulating VEGF
activity through competing to bind Flt-1. Besides its angio-
genic effect, we found that overexpression of PlGF in
transgenic mice resulted in increasing alveolar type II cell
apoptosis that caused enlarged airspace and pulmonary
emphysema, which is similar to BPD pathologically.12 The
aim of this study was to determine whether cord blood levels
of these angiogenic or antiangiogenic factors were associ-
ated with the development of BPD.
2. Methods
2.1. Study participants
In our previous studies,13e15 we studied the association
between PlGF level of cord blood and the incidence ofBPD,13 VEGF level and the incidence of respiratory distress
syndrome (RDS),14 and sFlt-1 level and the platelet count in
preterm infants.15 Cord blood was collected using a hepa-
rinized syringe during delivery. After 15 minutes of centri-
fugation, the levels of VEGF, PlGF, and sFlt-1 were
measured using a standardized sandwich enzyme-linked
immunosorbent assay method as previously
described.13e15 In this study, preterm infants who were
born less than gestational age (GA) of 35 weeks and who
already had all the data of cord blood levels of VEGF, PlGF,
and sFlt-1 from our previous studies, were enrolled. We
excluded those infants with either prenatal maternal
infection or neonatal infection within 3 days after birth. GA
was defined by the means of last menstrual age or ultra-
sonography exams. Prenatal steroids were routinely
administered during GA of 24 to 34 weeks when preterm
labor was possible. We defined (RDS) as acute respiratory
distress due to insufficiency of surfactant in the group of
prematurity requiring higher concentration of oxygen and
respiratory support based on radiographic characteristics.
Under this condition, exogenous surfactant was adminis-
tered via an endotracheal tube as quickly as possible when
a fraction of >40% oxygen was required to maintain the
blood oxygen level (SpO2) up to 90%. As for BPD, the defi-
nition was the necessity for supplemental oxygen or any
kind of ventilator support at postmenstrual age 36 weeks.
We also collected all demographic information and peri-
natal history from a detailed chart review.
2.2. Data analysis
We used the Mann-Whitney U test for comparison between
preterm infants with and without BPD, and multivariate
analysis with logistic regression to assess the association of
these molecules and the development of BPD.3. Results
In total, 56 preterm infants were included in this study.
Nineteen (34%) infants developed BPD. The BPD group had
lower GA [27 weeks (24e34 weeks) vs. 31 weeks (28e24
weeks), p < 0.001], lower birth body weight [882 g
(620e1232 g) vs. 1538 g (886e2328 g), p < 0.001], higher
incidence of antenatal steroid usage (89% vs. 56%,
p Z 0.012), higher incidence of RDS (58% vs. 14%,
pZ 0.001), and longer period of intubation [27 days (0e109
days) vs 0 days (0e24 days), p < 0.001]. In addition, the BPD
group had a higher level of PlGF as compared with those
infants without BPD [21.45 pg/dL (6.03e474.01 pg/dL) vs.
7.43 pg/dL (0.09e23.75 pg/dL), p < 0.001]. However, the
Table 2 Factors associated with the development of
bronchopulmonary dysplasia (BPD) in preterm infants.
OR (95% CI) p
GA 1.370 (0.991e1.894) 0.056
BBW 0.987 (0.976e0.998) 0.022
RDS 0.409 (0.28e6.045) 0.515
sFlt-1 0.998 (0.994e1.002) 0.254
VEGF 1.001 (0.997e1.004) 0.697
PlGF 1.515 (1.097e2.093) 0.012
BBW Z birth body weight; CI Z confidence interval;
GA Z gestational age; OR Z odds ratio; PlGF Z placental
growth factor; RDS Z respiratory distress syndrome;
sFlt-1 Z soluble fms-like tyrosine kinase-1; VEGF Z vascular
endothelial growth factor.
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tween these two groups (Table 1).
According to our previous study, the cord blood level of
PlGF was negatively correlated with GA,13 so we performed
multivariate analysis in order to clarify the importance of
PlGF in the development of BPD. Multivariate analysis with
logistic regression revealed that lower birth body weight
(p Z 0.022) and a higher level of PlGF (p Z 0.012) were
significantly correlated to the development of BPD inde-
pendently (Table 2). As for VEGF and sFlt-1, there was no
significant association with the development of BPD ac-
cording to our analysis.
4. Discussion
In this study, we demonstrated that among these angio-
genic and antiangiogenic factors, the level of PlGF rather
than sFlt-1 or VEGF was significantly elevated in preterm
infants with BPD. Consequently, the cord blood level of
PlGF may be used as a predictor for subsequent develop-
ment of BPD in preterm infants.
Exogenous surfactant replacement treats the functional
immaturity for preterm lungs; however, it does not over-
come the structural immaturity which remained a hallmark
of lung development arrest.16 Recent observations and
studies emphasized the importance of angiogenesis and
angiogenic factors during normal alveolar growth. Among
these angiogenic and antiangiogenic factors that we
investigated, the essential role of VEGF signaling was
repeatedly emphasized. Several animal studies disclosedTable 1 Characteristics and cord blood levels of angio-
genic factors and antiangiogenic factors of preterm infants
with and without bronchopulmonary dysplasia (BPD).
BPD Z 0
(n Z 37)
BPD Z 1
(n Z 19)
p
GA 31 (28e34) 27 (24e34) <0.001
BBW 1538 (886e2328) 882 (620e1232) <0.001
Gender M:F 19:18 11:8 0.645
Prenatal
steroid
20 (56%) 17 (89%) 0.012
RDS 5 (14%) 11(58%) 0.001
Surfactant 4 (11%) 6 (32%) 0.057
AS (10) 6 (0e9) 6 (0e9) 0.513
AS (50) 8 (0e10) 7 (5e9) 0.326
Intubation
days
0 (0e24) 27 (0e109) <0.001
sFlt-1 106.95
(35.8e1457.78)
146.04
(38.94e3600.46)
0.373
VEGF 18.821
(10.34e2390.6)
29.752
(11.81e311.7)
0.640
PlGF 7.43
(0.09e23.75)
21.45
(6.03e474.01)
<0.001
Data are presented as medians (ranges) and number (percent-
age).
ASZ Apgar score; BBWZ birth body weight; GAZ gestational
age; PlGFZ placental growth factor; RDSZ respiratory distress
syndrome; sFlt-1 Z soluble fms-like tyrosine kinase-1;
VEGF Z vascular endothelial growth factor.that inhibition of VEGF signaling indeed impaired alveola-
rization and disrupted normal lung growth.5,6,9e11,17,18
Furthermore, alveolarization was enhanced when VEGF
was additionally administered.18e20 By contrast, sFlt-1 is an
endogenous antagonist of VEGF signaling by capturing both
VEGF and PlGF. From previous studies focusing on the
relationship between sFlt-1 and preeclampsia, sFlt-1 was
shown to have the antiangiogenic capability to cause a
similar antiangiogenic state in the development of pre-
eclampsia.15,21e24 Recently, Tang et al9 demonstrated that
intra-amniotic injection of sFlt-1 resulted in reduced alve-
olar number and reduced pulmonary arterial density in
fetal rat lungs. All these findings indicated that adequate
angiogenesis is important for developing lungs. Besides the
angiogenic effects, some reports documented that PlGF
could also activate monocytes and result in increasing
proinflammatory cytochemokines.25,26 In addition, we pre-
viously demonstrated that PlGF overexpression transgenic
mice had an enlarged airspace which was similar to path-
ologic findings of chronic obstructive lung disease in adult
patients or BPD in preterm infants.12 We also found that
cord blood PlGF levels predicted poor pulmonary outcome
in preterm infants.13 By using PlGF knockout mice, we
showed that elastase-induced pulmonary emphysema could
be prevented by depleting PlGF in vivo.27 These studies all
suggested that PlGF may play an important role in chronic
inflammatory lung diseases.
Therefore, low VEGF, high sFlt-1, and high PlGF levels
tend to impair normal lung development. In our study, we
found the cord blood levels of VEGF and sFlt-1 did not differ
between preterm infants with or without BPD, although the
importance of these two molecules was reported. The BPD
group had significantly higher PlGF levels than the control
group. Of course, this does not mean that high PlGF levels
directly cause the subsequently developing BPD. Instead,
the association suggests that cord blood level of PlGF may
have the potential to be a useful predictor for the subse-
quently developing BPD in preterm infants.
The strength of this study is that it compares these three
common angiogenic and antiangiogenic factors together to
determine a biomarker to predict subsequently developing
BPD. However, our study also has some limitations. First,
this is not a case control study and the sample size is
limited. We only enrolled the preterm infants who had all
the data of cord blood PlGF, VEGF, and sFlt-1 levels.
Angiogenic Factors in Cord Blood 385Therefore, there may be selection bias. The association
between the PlGF level and BPD is consistent with our
previous report.13 Second, the definition of BPD used here is
a traditional clinical definition but not a physiological
definition, because this is a retrospective study. Therefore,
a large prospective and randomized control study is war-
ranted to confirm our finding.
5. Conclusion
Although perinatal care has improved significantly in recent
decades, there was no effective and definite treatment for
curing BPD or preventing BPD. In this study, we demon-
strated that the cord blood level of PlGF rather than VEGF
and sFlt-1 was significantly higher in preterm infants with
BPD. This finding is consistent with our previous report
which supported the idea that cord blood level of PlGF may
be considered as a biomarker to predict subsequent
developing BPD.
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